Literature DB >> 31882404

New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology.

Martin C Michel1, T J Murphy1, Harvey J Motulsky2.   

Abstract

The American Society for Pharmacology and Experimental Therapeutics has revised the Instructions to Authors for Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, and Molecular Pharmacology These revisions relate to data analysis (including statistical analysis) and reporting but do not tell investigators how to design and perform their experiments. Their overall focus is on greater granularity in the description of what has been done and found. Key recommendations include the need to differentiate between preplanned, hypothesis-testing, and exploratory experiments or studies; explanations of whether key elements of study design, such as sample size and choice of specific statistical tests, had been specified before any data were obtained or adapted thereafter; and explanations of whether any outliers (data points or entire experiments) were eliminated and when the rules for doing so had been defined. Variability should be described by S.D. or interquartile range, and precision should be described by confidence intervals; S.E. should not be used. P values should be used sparingly; in most cases, reporting differences or ratios (effect sizes) with their confidence intervals will be preferred. Depiction of data in figures should provide as much granularity as possible, e.g., by replacing bar graphs with scatter plots wherever feasible and violin or box-and-whisker plots when not. This editorial explains the revisions and the underlying scientific rationale. We believe that these revised guidelines will lead to a less biased and more transparent reporting of research findings.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Year:  2020        PMID: 31882404     DOI: 10.1124/mol.119.118927

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research.

Authors:  Nathalie Percie du Sert; Viki Hurst; Amrita Ahluwalia; Sabina Alam; Marc T Avey; Monya Baker; William J Browne; Alejandra Clark; Innes C Cuthill; Ulrich Dirnagl; Michael Emerson; Paul Garner; Stephen T Holgate; David W Howells; Natasha A Karp; Stanley E Lazic; Katie Lidster; Catriona J MacCallum; Malcolm Macleod; Esther J Pearl; Ole H Petersen; Frances Rawle; Penny Reynolds; Kieron Rooney; Emily S Sena; Shai D Silberberg; Thomas Steckler; Hanno Würbel
Journal:  Exp Physiol       Date:  2020-07-14       Impact factor: 2.969

2.  The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.

Authors:  Nathalie Percie du Sert; Viki Hurst; Amrita Ahluwalia; Sabina Alam; Marc T Avey; Monya Baker; William J Browne; Alejandra Clark; Innes C Cuthill; Ulrich Dirnagl; Michael Emerson; Paul Garner; Stephen T Holgate; David W Howells; Natasha A Karp; Stanley E Lazic; Katie Lidster; Catriona J MacCallum; Malcolm Macleod; Esther J Pearl; Ole H Petersen; Frances Rawle; Penny Reynolds; Kieron Rooney; Emily S Sena; Shai D Silberberg; Thomas Steckler; Hanno Würbel
Journal:  J Physiol       Date:  2020-07-14       Impact factor: 5.182

3.  Reduced Activation of the Synaptic-Type GABAA Receptor Following Prolonged Exposure to Low Concentrations of Agonists: Relationship between Tonic Activity and Desensitization.

Authors:  Spencer R Pierce; Allison L Germann; Alex S Evers; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

4.  Braylin induces a potent vasorelaxation, involving distinct mechanisms in superior mesenteric and iliac arteries of rats.

Authors:  W A Santos; K M C Dourado; F A Araújo; R L C Jesus; R A Moraes; S C D S Oliveira; Q L Alves; L O Simões; L L Casais-E-Silva; R S Costa; E S Velozo; D F Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-09       Impact factor: 3.000

5.  Targeted activation of midbrain neurons restores locomotor function in mouse models of parkinsonism.

Authors:  Débora Masini; Ole Kiehn
Journal:  Nat Commun       Date:  2022-01-26       Impact factor: 14.919

6.  The Sulfated Steroids Pregnenolone Sulfate and Dehydroepiandrosterone Sulfate Inhibit the α1β3γ2L GABAA Receptor by Stabilizing a Novel Nonconducting State.

Authors:  Spencer R Pierce; Allison L Germann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2021-12-01       Impact factor: 4.436

7.  Decoding Cinnabarinic Acid-Specific Stanniocalcin 2 Induction by Aryl Hydrocarbon Receptor.

Authors:  Nikhil Y Patil; Hui Tang; Iulia Rus; Kangling Zhang; Aditya D Joshi
Journal:  Mol Pharmacol       Date:  2021-11-11       Impact factor: 4.436

8.  Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.

Authors:  Mateusz P Czub; Adam M Boulton; Ettore J Rastelli; Nikhil R Tasker; Taber S Maskrey; Isabella K Blanco; Kelley E McQueeney; John H Bushweller; Wladek Minor; Peter Wipf; Elizabeth R Sharlow; John S Lazo
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

9.  A teaching tool about the fickle p value and other statistical principles based on real-life data.

Authors:  Salem Alawbathani; Mehreen Batool; Jan Fleckhaus; Sarkawt Hamad; Floyd Hassenrück; Yanhong Hou; Xia Li; Jon Salmanton-García; Sami Ullah; Frederique Wieters; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-14       Impact factor: 3.000

10.  Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate.

Authors:  Ru Huang; Yuhan Liu; Anna Ciotkowska; Alexander Tamalunas; Raphaela Waidelich; Frank Strittmatter; Christian G Stief; Martin Hennenberg
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.